Stocks · News reference
Wells Fargo Maintains Equal-Weight on ResMed, Lowers Price Target to $215
Wells Fargo analyst Nathan Treybeck maintains ResMed (NYSE:RMD) with a Equal-Weight and lowers the price target from $225 to $215.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 7, 2026, 2:11 PM
- Checked
- Aug 7, 2026, 2:11 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Rothschild & Co Initiates Coverage On ResMed with Neutral Rating, Announces Price Target of $230
Rothschild & Co analyst Jackson Philips initiates coverage on ResMed (NYSE:RMD) with a Neutral rating and announces Price Target of $230.
Read original at benzingaRBC Capital Maintains Sector Perform on ResMed, Raises Price Target to $244
RBC Capital analyst Craig Wong-Pan maintains ResMed (NYSE:RMD) with a Sector Perform and raises the price target from $234 to $244.
Read original at benzingaResMed shares are trading lower after multiple analyst firms lowered their respective price targets on the stock.
Read original at benzinga